These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10712165)

  • 1. DVT prevention. Low-molecular-weight heparin is a viable option.
    Benton L
    Am J Nurs; 2000 Feb; 100(2):84. PubMed ID: 10712165
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of venous thromboembolism after neurosurgery.
    Agnelli G
    Thromb Haemost; 1999 Aug; 82(2):925-30. PubMed ID: 10605805
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty.
    Colwell CW; Hardwick ME
    Clin Orthop Relat Res; 2006 Nov; 452():181-5. PubMed ID: 17016231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 7. [Indications and clinical application of thrombosis prophylaxis. I].
    Mittelkötter U; Reith HB; Thiede A
    Zentralbl Chir; 2000; 125(7):W49-52. PubMed ID: 10960979
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic therapy with low molecular weight heparin in cancer patients.
    Petralia P; Kakkar AK
    Eur J Med Res; 2004 Mar; 9(3):119-24. PubMed ID: 15096321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of low-molecular-weight heparins in treating thrombosis.
    Lee AY
    J Support Oncol; 2006 Mar; 4(3):123-4. PubMed ID: 16553137
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism.
    Prandoni P
    J Support Oncol; 2006 Mar; 4(3):127-8. PubMed ID: 16553138
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of deep vein thrombosis using low-molecular-weight heparins.
    Groce JB
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F; Faul C; Dichgans J; Weller M
    J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New medical anticoagulants].
    Choussat R; Montalescot G
    Rev Mal Respir; 1999 Nov; 16(5 Pt 2):985-95. PubMed ID: 10907447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis in immobilized medical patients.
    Vaitkus PT
    Eur J Med Res; 2004 Mar; 9(3):131-4. PubMed ID: 15096323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of venous thrombosis and pulmonary artery thromboembolism in non-surgical patients: specification of indications].
    Iavelov IS
    Ter Arkh; 2007; 79(9):70-9. PubMed ID: 18038592
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of deep vein thrombosis in cancer patients.
    Jahanzeb M
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S50-3. PubMed ID: 16280114
    [No Abstract]   [Full Text] [Related]  

  • 19. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
    Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D
    An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.